-
Is Celgene Considering Going Private?
biospace
March 16, 2018
Despite a deep pipeline and a market cap of $69.4 billion,?Celgene?shares are down 12 percent year to date.
-
Celgene strikes $101m partnership in oncology, neurodegenerative and inflammatory
pharmafile
March 06, 2018
Celgene has signed a new multi-year partnership agreement with biotech company Vividion Therapeutics
-
Celgene to tackle ‘undruggable’ targets with Vividion
pharmaphorum
March 06, 2018
Celgene has signed a deal with Vividion Therapeutics to develop drugs for oncology, inflammatory, and neurodegenerative diseases.
-
Celgene Announces Expiration of Cash Tender Offer for Shares of Juno Therapeutics, Inc.
biospace
March 06, 2018
Celgene Corporation (NASDAQ: CELG) announced today that its offer to acquire Juno Therapeutics, Inc
-
Vividion Therapeutics Snags $101M from Celgene
biospace
March 06, 2018
Celgene?continues to make friends in the biotech industry.
-
Ballsy Celgene Continues to Tread Carefully Into Neurosciences
biospace
January 29, 2018
Two years ago during a lunch with a group of reporters at the?J.P. Morgan?confab, then?Celgene?CEO (now executive chairman) Bob Hugin got my attention with a comment on the importance of neurosciences in the pipeline.
-
Celgene confirms $9B Juno buyout, sees $3B sales for JCAR017
fiercebiotech
January 23, 2018
Celgene has agreed to buy CAR-T specialist Juno Therapeutics for around $9 billion in a deal that instantly makes it a big cheese in this emerging therapeutic category.
-
Juno Explodes on Celgene Takeover Rumors
biospace
January 18, 2018
Rumors?that?Celgene Corporation?is in talks to acquire?Juno Therapeutics?has caused Juno’s stock to rocket more than 50 percent to $68.80 in premarket trading.
-
Celgene to Buy Impact Biomedicines for up to $7B
contractpharma
January 15, 2018
Celgene Corporation?and?Impact Biomedicines?today announced the signing of a definitive agreement in which Celgene will acquire Impact Biomedicines, which is developing fedratinib for myelofibrosis and polycythemia vera.
-
Celgene Scoops Up San Diego Biotech in $7B Deal
biospace
January 09, 2018
Celgene?began the week of the?J.P. Morgan Healthcare Conference?with a?$7 billion announcement. The company said it will acquire San Diego-based?Impact Biomedicines?and its JAK inhibitor progra
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight July 2025
